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Introduction: GlycA is a novel inflammatory biomarker measured using nuclear magnetic resonance (NMR). Its
NMR signal primarily represents glycosylated acute phase proteins. GlycA was associated with inflammation and
development of cardiovascular disease in initially healthy women. We hypothesized that GlycA is a biomarker of
disease activity and is associated with coronary artery atherosclerosis in patients with rheumatoid arthritis (RA).
Methods: We conducted a cross-sectional study of 166 patients with RA and 90 control subjects. GlycA was
measured from an NMR signal originating from N-acetylglucosamine residues on circulating glycoproteins. The
relationship between GlycA and RA disease activity (Disease Activity Score based on 28 joints (DAS28)) and coronary
artery calcium score was determined.
Results: GlycA concentrations were higher in patients with RA (median (interquartile range): 398 μmol/L (348 to
473 μmol/L)) than control subjects (344 μmol/L (314 to 403 μmol/L) (P < 0.001). In RA, GlycA was strongly correlated
with DAS28 based on erythrocyte sedimentation rate (DAS28-ESR) and DAS28 based on C-reactive protein (DAS28-CRP)
and their components, including tender and swollen joint counts, global health score, ESR and CRP (all P < 0.001).
The area under the receiver operating characteristic curve for GlycA’s ability to differentiate between patients with
low versus moderate to high disease activity based on DAS28-CRP was 0.75 (95 % confidence interval (CI): 0.68,
0.83). For each quartile increase in GlycA, the odds of having coronary artery calcium increased by 48 % (95 % CI:
4 %, 111 %), independent of age, race and sex (P = 0.03).
Conclusion: GlycA is a novel inflammatory marker that may be useful for assessment of disease activity and is
associated with coronary artery atherosclerosis in patients with RA.Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory auto-
immune disorder affecting nearly 1 % of the US popula-
tion. Tight control of disease activity, including monitoring
of acute-phase reactants, is important to reduce joint
destruction and disability in RA [1]. Currently, many rheu-
matologists consider that monitoring an acute-phase react-
ant is standard of care in RA management [2]. Indeed,
measurement of C-reactive protein (CRP) or erythrocyte
sedimentation rate (ESR) is incorporated into the Disease
Activity Score based on 28 joints (DAS28) [3], the core set* Correspondence: michelle.ormseth@vanderbilt.edu
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stated.of RA disease activity measures proposed by the American
College of Rheumatology [4] and the American College of
Rheumatology/European League Against Rheumatism RA
remission criteria [5].
The markers of inflammation most commonly used to
assess RA disease activity—ESR and CRP—have disadvan-
tages. For example, ESR is altered by non-inflammatory
conditions such as chronic kidney disease [6], pregnancy,
anemia, abnormal red blood cell shape or size, and serum
protein concentrations [7]. Because some of these con-
founding influences are unrelated to RA disease activity,
the current treat-to-target recommendations include cau-
tions about the use of ESR for monitoring RA activity [2].
Furthermore, CRP exhibits high variability over time in
patients without inflammatory diseases [8–10], potentiallyal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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at one time point. Moreover, both ESR and CRP increase
with age [11], female sex [12, 13] and body mass index
(BMI) [14–17]. Thus, an alternative marker of inflamma-
tion not affected by some of these factors would be useful
for assessing RA disease activity.
GlycA is a nuclear magnetic resonance (NMR) signal
derived from mobile N-acetyl methyl groups, specifically
the N-acetylglucosamine and N-acetylgalactosamine moi-
eties, on the carbohydrate side chains of glycosylated
proteins [18–20]. GlycA can be measured in the NMR
spectra acquired for the quantification of serum or plasma
lipoprotein particle numbers [10]. The majority of circu-
lating glycosylated proteins are acute-phase proteins [18],
and the main contributors to the GlycA signal are α1-acid
glycoprotein, α1-antitrypsin, haptoglobin, α1-antichy-
motrypsin and transferrin [10]. Glycosylated immuno-
globulin is not a main contributor to the GlycA signal,
however [10].
GlycA is emerging as a new marker of inflammation
and cardiovascular (CV) risk. GlycA concentrations were
associated with known inflammatory markers, such as
CRP, interleukin-6 (IL-6) and fibrinogen in 5,537 partici-
pants of the Multi-Ethnic Study of Atherosclerosis [10].
Moreover, GlycA was associated with incident CV events.
For example, for every 1 standard deviation (SD) increase
in baseline GlycA concentration, there was a 34 % in-
creased incidence of CV events within the first 6 years of
follow-up, independent of traditional risk factors, in over
27,000 women from the Women’s Health Study [21]. Lit-
tle is known about GlycA concentrations in RA. We hy-
pothesized that GlycA is a marker of disease activity and
CV risk in patients with RA.
Methods
Study population
We conducted a cross-sectional study that included 166
patients with RA and 90 control subjects from a cohort
of patients extensively characterized for CV risk [22].
Recruitment and study procedures, as well as predictors
of coronary atherosclerosis, in this cohort have been
described previously [22–30]. All subjects were older
than 18 years of age, and patients with RA fulfilled the
1987 American College of Rheumatology classification
criteria for RA [31]. The RA and control groups were
frequency-matched for age, race and sex, and control
subjects did not have RA or other inflammatory disease.
Patients with RA were identified from an early RA regis-
try, Vanderbilt University Medical Center or local rheuma-
tologist referral, or advertisement. Control subjects were
recruited from patient acquaintances, advertisement or
volunteer database. Consecutive eligible patients were
enrolled. The study was approved by the Vanderbilt
University Medical Center Institutional Review Board,and all subjects gave us their written informed consent
to participate.
Clinical and laboratory data
Clinical information, laboratory measurements and coron-
ary artery calcium scores were obtained as described pre-
viously [22]. Disease activity of RA was determined on the
basis of the DAS28-ESR and DAS28-CRP [3]. Categories
of disease activity based on the DAS28-ESR were defined
as follows [32]: remission = DAS28 < 2.6, low =DAS28-
ESR between 2.6 and 3.2, moderate = DAS28-ESR between
3.2 and 5.1, and high = DAS28-ESR >5.1. Categories of
disease activity based on the DAS28-CRP were defined as
follows [32]: remission = DAS28-CRP <2.3, low =DAS28-
CRP between 2.3 and 2.7, moderate = DAS28-CRP be-
tween 2.7 and 4.1, and high =DAS28-CRP >4.1. Prevalent
coronary artery disease was defined as a history of myo-
cardial infarction; coronary procedure such as stenting,
balloon angioplasty or coronary artery bypass surgery;
or angina. Estimated glomerular filtration rate (eGFR)
was calculated using the Modification of Diet in Renal
Disease Study formula [33]: eGFR (ml/min/1.73 m2) =
175 × (serum creatinine) − 1.154 × (age) − 0.203 × (0.742
if female) × (1.212 if African American).
ESR was measured at the Vanderbilt University Med-
ical Center Clinical Laboratory, and high-sensitivity CRP
was measured at the same laboratory or by enzyme-linked
immunosorbent assay (ELISA) (EMD Millipore, Billerica
MA, USA). Tumor necrosis factor α (TNFα) and IL-6
concentrations were measured by multiplex ELISA (EMD
Millipore).
Larsen score measurement
The Larsen score was calculated in 92 patients with RA
based on radiographs of the hands and feet as described
previously [34]. The radiographs were obtained a median
of 1.9 years (interquartile range (IQR): 1.1 to 2.7) prior
to study enrollment and scored by a blinded single investi-
gator (TS). Larsen score was quantified by assessing the
damage to 20 joints (wrists, first to fifth metacarpophalan-
geal joints and second to fifth metatarsophalangeal joints),
yielding a total score ranging from 0 to 100 [35, 36].
Coronary artery calcium score measurement
Coronary artery calcium scores were calculated by per-
forming electron beam computed tomography with an
Imatron C-150 scanner (GE Medical Systems/Imatron,
South San Francisco, CA, USA), as previously described
[22], and quantified in Agatston units [37].
GlycA measurement
NMR spectra were acquired from ethylenediaminetetra-
acetic acid plasma samples as previously described for the
NMR LipoProfile (lipoprotein particle) test at LipoScience
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is comprised of a 9.4-T (400-MHz 1H frequency) spec-
trometer (Bruker BioSpin, Billerica, MA, USA) with an in-
tegrated fluidic sample delivery system. The GlycA signal
was quantified using proprietary deconvolution software
that uses a non-negative linear least squares algorithm to
fit the experimental signal to individual spectral compo-
nents, including proteins and lipoproteins as well as sig-
nals representing the GlycA NMR resonance [10]. GlycA
concentrations were quantified from these spectra without
knowledge of any subject characteristics. The intra-assay
and inter-assay variabilities for GlycA measurement are
1.9 % and 2.6 %, respectively [10].Table 1 Participant characteristicsa
RA (n = 166) Control
(n = 90)
P-value
Median age (IQR), yr 54 (45 to 63) 53 (44 to 60) 0.38
Caucasian race, n (%) 147 (89) 77 (86) 0.55
Female sex, n (%) 114 (69) 56 (62) 0.30
RF-positive, n (%) 114 (72) – –
Median DAS28-ESR (IQR) 3.86 (2.63–4.90) – –
Median DAS28-CRP (IQR) 3.09 (2.06–3.80) – –
Tender joints, n (IQR) 2 (0 to 7) – –
Swollen joints, n (IQR) 3 (0 to 8) – –
Median CRP (IQR), mg/L 4.0 (1.2 to 11) 0.5 (0.2 to 1.5) <0.001
Median ESR (IQR), mm/hr 15 (7 to 36) – –
Known CAD, n (%) 17 (10) 9 (10) 0.95
Coronary artery calcium,
n (%)
83 (52) 34 (39) 0.05
Coronary calcium score,
Agatston units
2.7 (0 to 178.7) 0 (0 to 19.2) 0.02
Methotrexate use, n (%) 118 (71) – –
Leflunomide use, n (%) 29 (18) – –
Hydroxychloroquine use,
n (%)
42 (25) – –
Anti-TNFα agent use, n (%) 33 (20) – –
Prednisone use, n (%) 89 (54) – –
NSAID use, n (%) 55 (33) 33 (37) 0.53
aRF data were available in 159 patients with RA. Coronary artery calcium
scores were available for 161 patients with RA and 88 control subjects. CAD,
Coronary artery disease; CRP, High-sensitivity C-reactive protein; DAS28,
Disease Activity Score based on 28 joints; ESR, Erythrocyte sedimentation rate;
IQR, Interquartile range; NSAID, Non-steroidal anti-inflammatory drug; RA,
Rheumatoid arthritis; RF, Rheumatoid factor; TNFα, Tumor necrosis factor αStatistics
On the basis of a fixed sample size of 166 patients with
RA and 90 control subjects and the SD of GlycA 57 μmol/
L in control subjects, our study had 90 % power to detect
a difference of approximately 25 μmol/L GlycA concentra-
tion between RA and control subjects. On the basis of the
Women’s Health Study, a 1 SD increase in GlycA was in-
dependently associated with a 34 % increased rate of CV
events within 6 years of follow-up [21]; thus, the study
had sufficient power for us to detect a clinically meaning-
ful difference in GlycA.
Descriptive statistics were calculated as medians with
IQRs (25th to 75th percentiles) for continuous variables
and as frequency and proportions for categorical variables.
To compare variables between RA and control subjects,
the Wilcoxon rank-sum test was used to compare continu-
ous variables and the Pearson χ2 test was used to compare
categorical variables. Correlation between GlycA concen-
trations and variables of interest was determined by Spear-
man correlation.
The ability of GlycA concentrations to differentiate be-
tween low and moderate to high disease activity, defined
on the basis of the DAS28-ESR and DAS28-CRP values,
was examined by calculating the area under the receiver
operating characteristic (AUC) curve.
The association between quartiles of GlycA concentra-
tions and presence of coronary artery calcium as well as
presence of coronary artery disease was assessed by bin-
ary logistic regression. In these models, the presence of
coronary artery calcium or a previous diagnosis of cor-
onary artery disease was the dependent variable and
GlycA was the independent variable. Separate analyses
were performed, adjusting for age, race, and sex and
adjusting for components of Framingham Risk Score,
which we have termed traditional CV risk factors (age,
sex, total cholesterol, high-density lipoprotein (HDL)
cholesterol, smoking status, systolic blood pressure and
anti-hypertensive use) [39], and then additionally for
the presence of diabetes.Data analysis was performed using IBM SPSS Statistics
version 22 software (IBM, Armonk, NY, USA). Two-sided
P-values <0.05 were considered statistically significant.Results
Clinical characteristics
Patients with RA and control subjects were of similar
age, race and sex (Table 1). In patients with RA, the me-
dian (IQR) DAS28-ESR and DAS28-CRP were 3.86 units
(2.63 to 4.90 units) and 3.09 units (2.06 to 3.80 units),
respectively. Patients with RA had higher CRP concen-
trations than control subjects (P < 0.001). The majority
of patients with RA were taking methotrexate (71 %)
and prednisone (54 %), and 20 % were taking an anti-
TNFα agent (Table 1). Approximately 10 % of both RA
and control subjects had known coronary artery disease,
and coronary artery calcium was present in 52 % of
patients with RA and 39 % of control subjects. GlycA
concentrations were higher in patients with RA (median
(IQR): 398 μmol/L (348 to 473 μmol/L)) compared with
RA Disease Activity









Fig. 2 GlycA increases with increasing rheumatoid arthritis disease
activity. Boxes represent the median (middle horizontal line) and the
25th and 75th percentiles. Whiskers represent the 5th and 95th
percentiles. Each data point is presented as an open circle. Rheumatoid
arthritis (RA) disease activity on the basis of Disease Activity Score
based on 28 joints using erythrocyte sedimentation rate (DAS28-ESR)
was defined as follows: remission = DAS28 < 2.6 (n = 39); low = DAS28
between 2.6 and 3.2 (n = 25); moderate = DAS28 between 3.2 and 5.1
(n = 67); and high = DAS28 > 5.1 (n = 33)
Table 2 Association between GlycA, C-reactive protein and
erythrocyte sedimentation rate with measures of disease activity
and clinical characteristics in patients with rheumatoid arthritisa
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0.001) (Fig. 1).
GlycA relationship to disease activity in rheumatoid
arthritis and disease-related factors
Increasing GlycA concentrations were significantly asso-
ciated with increasing RA disease activity (P < 0.001)
(Fig. 2). GlycA was correlated with DAS28-ESR (Spear-
man ρ = 0.58, P < 0.001) and DAS28-CRP (ρ = 0.47, P <
0.001). These correlations were similar or slightly stron-
ger than those between CRP and DAS28-ESR (ρ = 0.48,
P < 0.001) and between ESR and DAS28-CRP (ρ = 0.36,
P < 0.001) (Table 2). Similarly, the cross-sectional rela-
tionship between Larsen score and GlycA (ρ = 0.24, P =
0.02) was similar or slightly stronger than the relation-
ship with CRP (ρ = 0.18, P = 0.09) or ESR (ρ = 0.16, P =
0.13) (Table 2).
The AUC for GlycA’s ability to discriminate between
patients with low versus moderate to high disease activ-
ity was 0.78 (95 % CI: 0.71, 0.86) based on DAS28-ESR
and 0.75 (0.68, 0.83) based on DAS28-CRP. Such discrim-
ination was similar or better with GlycA compared with
ESR (AUC: 0.68 (95 % CI: 0.60, 0.76)) using DAS28-CRP
and compared with CRP (AUC: 0.74 (95 % CI: 0.67, 0.82))
using DAS28-ESR. GlycA was also associated with com-
ponents of the DAS28 scores including tender and swollen
joint counts, patient-reported global health score, ESR and
CRP (all P < 0.001) (Table 2).
The relationship between GlycA concentrations and
radiographic damage was assessed in a subset of 92 pa-
tients with RA for whom radiographic data were obtained.















Fig. 1 GlycA is higher in patients with rheumatoid arthritis
compared with control subjects. Boxes represent the median
(middle horizontal line) and the 25th and 75th percentiles. Whiskers
represent the 5th and 95th percentiles. Each data point is presented
as an open circle. Patients with rheumatoid arthritis had a higher
GlycA concentration (median (interquartile range): 398 μmol/L (348
to 473 μmol/L)) compared with control subjects (344 μmol/L (314 to
403 μmol/L); P < 0.001)0.24, P = 0.02) (Table 2). GlycA concentration was not sig-
nificantly different between rheumatoid factor–positive
(median (IQR) 408 μmol/L (351 to 479 μmol/L) and
rheumatoid factor–negative patients with RA (385 μmol/L
(336 to 452 μmol/L) (P = 0.09). Also, there were noGlycA ESR CRP
ρ ρ ρ
DAS28-ESR 0.58b 0.65b 0.48b
DAS28-CRP 0.47b 0.36b 0.50b
Tender joints 0.28b 0.12 0.16c
Swollen joints 0.29b 0.28b 0.29b
Global health score 0.25b 0.21c 0.22c
Larsen scored 0.24c 0.16 0.18
ESR 0.64b – 0.59b
CRP 0.61b 0.59b –
IL-6 0.39b 0.38b 0.40b
TNFα 0.25c 0.28b 0.21c
Age 0.04 0.18c 0.08
BMI 0.08 0.09 0.17c
Hemoglobin −0.12 −0.51b −0.21c
eGFR 0.02 −0.04 0.05
aCorrelation data are based on Spearman’s correlation coefficient (ρ). BMI,
Body mass index; CRP, High-sensitivity C-reactive protein; DAS28, Disease
Activity Score based on 28 joints; eGFR, Estimated glomerular filtration rate; ESR,
Erythrocyte sedimentation rate; IL-6, Interleukin-6; TNFα, Tumor necrosis factor α.
bP ≤ 0.001. cP < 0.05. dLarsen scores were available for 92 patients with RA
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tients with RA who were receiving methotrexate, lefluno-
mide, hydroxychloroquine, corticosteroids, anti-TNFα
agents, non-steroidal anti-inflammatories, anti-
hypertensives or statins compared with those not re-
ceiving the respective drugs (all P > 0.07).
Relationship between GlycA and subclinical
atherosclerosis in rheumatoid arthritis
We examined the cross-sectional relationship between
GlycA and the presence of coronary artery calcium, a
marker of subclinical atherosclerosis (Table 3). Among pa-
tients with coronary artery calcium, the median (IQR)
GlycA concentration was 415 μmol/L (356 to 477 μmol/L),
which trended higher than the median GlycA concentra-
tion of those without coronary calcium (379 μmol/L ([337
to 457 μmol/L)) (P = 0.06). For each quartile increase in
GlycA, the odds of having coronary artery calcium in-
creased by 48 % (95 % CI: 4 %, 111 %), independent of age,
race and sex (P = 0.03). This relationship was attenuated
after adjustment for traditional CV risk factors, including
age, sex, total cholesterol, HDL cholesterol, smoking status,
systolic blood pressure and anti-hypertensive use (P =
0.07), and additionally for diabetes (P = 0.12). Although
only 17 of 166 patients with RA had a diagnosis of estab-
lished coronary artery disease, we performed an explora-
tory analysis to determine the relationship between GlycA
and prevalent coronary artery disease. Among patients
with coronary artery disease, the median (IQR) GlycA
concentration was 453 μmol/L (380 to 487 μmol/L), which
was significantly higher than the median GlycA concentra-
tion of those without coronary artery disease (395 μmol/L
(344 to 487 μmol/L) (P = 0.03). Similarly, with each quartile
increase in GlycA, the odds of having a diagnosis of coron-
ary artery disease increased 110 % (17 % to 277 %), inde-
pendent of age, race and sex (P = 0.01), and remained
significant with additional adjustment for traditional CV
risk factors (P = 0.01) and additionally for diabetes (P =
0.02) (Table 3).
Relationship between potential confounders and GlycA
As discussed above, CRP and ESR have been reported
to be altered by age, sex and BMI. We found no signifi-
cant association between either age or BMI and GlycA
concentration (all P ≥ 0.30) (Table 2), and we observedTable 3 Relationship between GlycA and cardiovascular diseasea
GlycA OR (95 % CI) P-value ORb (95 % CI) Ad
P-v
Coronary calcium 1.32 (0.99, 1.74) 0.06 1.48 (1.04, 2.11) 0.0
Known CAD 1.83 (1.10, 3.03) 0.02 2.10 (1.17, 3.77) 0.0
aAll analyses were performed using logistic regression. CAD, Coronary artery disease
concentration. bAdjusted for age, race and sex. cAdjusted for age, sex, total choleste
pressure and anti-hypertensive use. dAdjusted for age, sex, total cholesterol, HDL ch
and diabetesno difference between men and women (P = 0.31). Simi-
larly, because anemia and impaired renal function may
alter ESR, we compared the association between GlycA
and hemoglobin and eGFR. There was no significant
correlation between GlycA and hemoglobin or eGFR (all
P > 0.60) (Table 2). Conversely, CRP was significantly cor-
related with BMI (positively) and hemoglobin (inversely),
and ESR was significantly correlated with age (positively)
and hemoglobin (inversely) (Table 2). Neither CRP nor
ESR was significantly correlated with eGFR. However,
most patients in this cohort had normal renal function
(median eGFR: 87 ml/min/1.73 m2 (IQR: 74 to 103 ml/
min/1.73 m2), range: 28 to 161 ml/min/1.73 m2).
Discussion
The major new findings of the present study are that
GlycA may be a useful marker of disease activity and CV
risk in patients with RA. GlycA was strongly correlated
with all components of DAS28 scores and was correlated
with radiographic damage in cross-sectional analysis.
Moreover, it was associated with the presence of coron-
ary artery calcium and prevalent coronary artery disease
in patients with RA.
GlycA is measured from an NMR signal that primarily
represents glycosylated acute-phase proteins [10, 18]. Gly-
cosylation, not to be confused with the non-enzymatic
binding of simple sugars as occurs with hemoglobin A1c
in patients with diabetes mellitus [40], is an enzymatic
modification whereby an oligo or polysaccharide moiety is
attached to a protein or lipid. This modification has an
important role in protein folding and stabilization, cell sig-
naling, cellular adhesion and antigen recognition [41]. In
fact, during an acute-phase response, not only are levels
of serum acute phase glycoproteins altered, but their
glycan structures are also dynamically modified by cir-
culating glycosidases and glycosyltransferases [42, 43].
Therefore, the measurement of these protein glycans via
NMR (GlycA) incorporates alterations in both protein
and glycan concentrations that occur during inflamma-
tory responses.
Previous studies have identified glycosylation products
as markers of RA and inflammatory disease. In one study
[19], 47 patients with RA and 51 control subjects were
followed longitudinally and metabolic profiles using NMR
spectroscopy were assessed over time from plasmajusted
alueb
ORc (95 % CI) Adjusted
P-valuec
ORd (95 % CI) Adjusted
P-valued
3 1.39 (0.97, 2.01) 0.07 1.35 (0.93, 1.95) 0.12
1 2.14 (1.17, 3.92) 0.01 2.10 (1.13, 3.88) 0.02
; CI, Confidence interval; OR, Odds ratio per quartile increase in GlycA
rol, high-density lipoprotein (HDL) cholesterol, smoking status, systolic blood
olesterol, smoking status, systolic blood pressure, anti-hypertensive use
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ing the GlycA signal), cholesterol, lactate and unsaturated
lipids appeared to be biomarkers of the presence of RA,
but these measures used together were not robust markers
of changes in RA disease activity [19]. Others found that
NMR measurements of total glycosylated residues (includ-
ing the signal for GlycA) and of N-acetylglucosamine (a
component of GlycA) plus N-acetylneuraminic acid were
elevated in 21 patients with rheumatic or infectious dis-
eases compared with 186 control subjects or patients with
cancer [20]. Although previous authors have shown inter-
esting correlations between the NMR signal arising from
glycosylated proteins and various disease states, the stan-
dardized measurement of GlycA from the profile spectra
obtained on a clinical NMR analyzer allows for more ro-
bust clinical investigations.
Given that the GlycA peak represents glycosylated
acute-phase proteins, it is not surprising that GlycA is
closely associated with disease activity in RA. Interest-
ingly, GlycA correlated at least as well as CRP or ESR
with several measures of disease activity, radiographic
damage and presence of coronary calcium. Moreover,
GlycA had similar discriminative capacity to differentiate
between low and moderate to high disease activity (AUC:
0.75) compared with published data for the multibiomar-
ker disease activity test (AUC: 0.76) in which CRP was
used as a component of both the predictor multibiomar-
ker test and outcome of disease activity measured by
DAS28-CRP [44].
Correlations with disease activity in a cross-sectional
study may be stronger with GlycA than with CRP or
ESR if GlycA is a more stable marker of inflammation
that is less susceptible to alterations by both day-to-day
variability and non-inflammatory factors. Indeed, the day-
to-day variability of GlycA concentrations is lower than
for CRP [10]. The speed at which GlycA rises and falls
after an inflammatory stimulus is not known; however,
given its components, it is likely that GlycA rises over sev-
eral days and falls over several weeks. This is similar to
the pattern of ESR’s rise and fall due to fibrinogen’s impact
on ESR [45], though fibrinogen is not a component of
GlycA. Interestingly, GlycA appears to be influenced less
by non-inflammatory conditions such as age, anemia, and
BMI than by CRP or ESR.
Our findings in patients with RA are concordant with
findings in the general population. GlycA was measured
in participants of the Women’s Health Study, which
included 27,491 women with a median of 17.2 years of
follow-up [21]. GlycA concentrations were correlated
strongly with CRP (ρ = 0.61, P < 0.0001), and baseline
GlycA concentrations were associated with incident CV
events. For example, within the first 6 years of follow-
up, the hazard ratio Q4 for CV events was 1.34 (95 %
CI: 1.22, 1.48) (P < 0.0001 for each 1 SD increase inGlycA). Notably, this unit of increase is similar to the
observed difference in GlycA concentration between
RA and control subjects in the present study.
We have evaluated the use of a novel inflammatory
marker for utility in assessing disease activity and CV
risk. There are other novel biomarkers that have simi-
larly been proposed as important biomarkers of both RA
disease activity and atherosclerosis or CV disease. Some
recent examples include osteoprotegerin [46, 47] and
angiopoietin-2 [48].
Although we included a relatively large cohort of pa-
tients with RA who were well characterized with respect
to inflammation and CV risk, the present study has limita-
tions. The adjusted analyses for the relationship between
GlycA and prevalent coronary artery disease should be
interpreted with caution because models were overfitted,
owing to the relatively small number of patients with RA
and prevalent coronary artery disease (N = 17). Because
this was a cross-sectional study, the longitudinal implica-
tions of the findings regarding an association are uncer-
tain. For example, although the finding that GlycA was
associated with radiographic damage is interesting, add-
itional studies are required to determine if GlycA has util-
ity as a marker of the risk of radiographic progression.
Moreover, future investigation of GlycA’s ability to meas-
ure changes in disease activity in response to therapy and
development of CV events is important to fully evaluate
its utility in patients with RA.
Conclusions
GlycA is increased in patients with RA compared with
control subjects. It is strongly correlated with DAS28 and
its components, and it is also correlated with radiographic
damage. Moreover, increased GlycA concentrations are as-
sociated with the presence of coronary artery calcification.
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